PERTH, Australia – The Australian government's Medical Technology, Biotechnology and Pharmaceutical Industry Growth Center (MTPConnect) launched a new node in Western Australia to support the state's burgeoning life sciences sector, and it is continuing to build up skill sets in the country to prepare for future needs.
PERTH, Australia – Australian stem cell therapy company Mesoblast Ltd. is on its way to filing a BLA for its allogeneic mesenchymal precursor cell therapy, after it showed strong survival rates in children with acute steroid-refractory graft-vs.-host disease (aGVHD) at six months.
PERTH, Australia – Biotron Ltd. is crunching the data from a recently concluded phase II trial in HIV-1 that tested its lead compound BIT-225 in combination with antiretroviral (ARV) drugs, and the Melbourne-based company said it believes its approach to tackling viruses like HIV could wipe out the virus completely, Biotron CEO Michelle Miller told BioWorld.
PERTH, Australia – Following its IPO on Australia's Securities Exchange last year, radiopharma company Telix Pharmaceuticals Ltd. has been building global partnerships to prepare for a commercial build-up of its theranostic radiopharmaceuticals. To add to its arsenal, Telix has exercised an option to acquire Atlab Pharma SAS for $10 million to de-risk its prostate cancer monoclonal antibody (MAb), TLX-591.
PERTH, Australia – Cellmid Ltd.'s lead anti-midkine antibody, CAB-102, reduced kidney injury and preserved renal function in a preclinical model of focal segmental glomerulosclerosis (FSGS), according to studies performed at the Westmead Institute in New South Wales.
PERTH, Australia – Following its IPO on Australia's Securities Exchange last year, radiopharma company Telix Pharmaceuticals Ltd. has been building global partnerships to prepare for a commercial build-up of its theranostic radiopharmaceuticals. To add to its arsenal, Telix has exercised an option to acquire Atlab Pharma SAS for $10 million to de-risk its prostate cancer monoclonal antibody (MAb), TLX-591.
PERTH, Australia – Cellmid Ltd.'s lead anti-midkine antibody, CAB-102, reduced kidney injury and preserved renal function in a preclinical model of focal segmental glomerulosclerosis (FSGS), according to studies performed at the Westmead Institute in New South Wales.
